Krystal Biotech, Inc. vs Johnson & Johnson
KRYS vs JNJ — side-by-side comparison from reported financials. KRYS leads 5, JNJ leads 5 of 10 comparable metrics.
Krystal Biotech, Inc.
KRYS · Healthcare
$331.61+1.32%Strained
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | KRYS | JNJ |
|---|---|---|
| Price | $331.61 | $261.79 |
| Market cap | $9.82B | $631B |
| Revenue (TTM) | $440M | $97.9B |
| Revenue growth | +22.6% | +5.6% |
| Net margin | 54.8% | 21.5% |
| Free cash flow | $258M | $22.2B |
| Net cash (debt) | $818M | ($27.8B) |
| 1-year price return | +75.7% | +37.0% |
| P/E | 40.6 | 29.9 |
| P/E vs own history (cheap-side %) | 63% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 19% | 26% |
| CV checks passed | 7 of 10 | 10 of 10 |
| Employees | 295 | 140,800 |
Full résumé-style profiles: KRYS CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.